Lepto4 Vaccine

The only canine leptospirosis vaccine with two critical indications. Featuring an even higher level of quality due to VacciPure filtration.

NOBIVAC LEPTO4 PROVIDES PROVEN PROTECTION AGAINST LEPTOSPIROSIS

The four-way leptospirosis vaccine is shown to be effective against disease, mortality, and leptospiruria.

  • Aid in the prevention of disease and mortality caused by 4 virulent Leptospira serovars21
  • Protects against liver dysfunction and thrombocytopenia1
  • The only vaccine shown to be effective against mortality and leptospiruria.
  • Significantly reduced leptospiremia15
  • Proven safe and well tolerated in multiple studies1
  • Available in both a monovalent and combination formulation (DAPPv)

INDICATIONS:

Shown to be effective for vaccination of healthy dogs 8 weeks of age or older against Leptospira canicola, L. icterohaemorrhagiae, L. pomona and L. grippotyphosa. Also effective against mortality and leptospiruria caused by L. canicola, L. icterohaemorrhagiae, L. pomona and L. grippotyphosa.

Aids in the prevention of leptospiruria associated with L. pomona.

Recommended for use in healthy dogs 8 weeks of age or older.

Unmatched Protection of Nobivac® Lepto4:

2 Critical Indications

1. SHEDDING: DEFENSE AGAINST URINARY SHEDDING CAUSED BY 4 KEY LEPTOSPIRA SEROVARS

PREVENT URINARY SHEDDING OF LEPTOSPIRES15

A key objective of vaccination is to prevent urinary shedding of leptospires, which has potential zoonotic risk:5,15
  • 0% of dogs vaccinated with Nobivac® Canine 1-DAPPv+L4 developed leptospiruria
  • All of the control dogs challenged with L. canicola and L. grippotyphosa, 80% of control dogs challenged with L. icterohaemorrhagiae, and 50% of control dogs challenged with L. pomona developed leptospiruria
Nobivac® Lepto4 prevents leptospiruria associated with
  • L. prippotyphosa
  • L. canicola
  • L. icterohaemorrhagiae
Nobivac® Lepto4 aids in the prevention of leptospiruria associated with
  • L. pomona

2. MORTALITY: THE ONLY LEPTOSPIROSIS VACCINE INDICATED TO AID IN THE PREVENTION OF DISEASE AND MORTALITY

PROTECTION FOR DOGS FACING THE MOST SEVERE CHALLENGES14

  • No dogs vaccinated with Nobivac® Canine 1-DAPPv+L4 died or required euthanasia
  • 54% mortality and euthanasia in control groups, reflecting the severity of challenge

Clinical efficacy results showed that Nobivac® Canine 1-DAPPv+L4 also prevented1

  • Leptospiremia
    • More than 85% of vaccinates had no leptospiremia; leptospires were cleared quickly from the blood in those that did
    • By contrast, all control dogs had leptospiremia, and it lasted significantly longer, by days
  • Liver dysfunction
    • Serum levels of bilirubin and AST* remained at normal levels in significantly more vaccinates
  • Thrombocytopenia
    • Platelet counts remained in the normal range

* AST = aspartate aminotransferase

UNMATCHED PROTECTION

NOBIVAC® LEPTO4 IS THE CLEAR CHOICE WHEN COMPARED WITH OTHER 4-WAY LEPTOSPIROSIS VACCINES6–9

No items to show.

Loading…

VacciPure

Filtration Technology

REDUCED TOTAL PROTEINS THROUGH VACCIPURE

Fewer total proteins (TP) means a more purified final product, which may reduce unwanted immune system responses, such as vaccine reactions.1

 

THE ADVANCED VACCIPURE™ FILTRATION TECHNOLOGY

watch

FILTRATION PROCESS LEADS TO IMPROVED VACCINES1

To promote an even higher level of vaccine quality, Merck Animal Health introduced the special VacciPure filtration process in manufacturing Nobivac® Lepto4 and Nobivac® Canine 1-DAPPV+L4

A porous filtration membrane selectively removes extraneous proteins, salts, and solvents

  • The outcome – fewer total proteins and a more purified final product
watch

No items to show.

Loading…

NOBIVAC® LEPTO4 IS A SAFE CHOICE FOR DOGS

  • Safety confirmed in a 749-dog field study1
  • Well tolerated on subcutaneous administration
  • Proven safe across a variety of breeds and ages
  • Now featuring an even higher level of quality due to the VacciPure filtration

ADMINISTRATION AND DOSAGE

  • Subcutaneous injection
  • Two 1 mL doses given 2-4 weeks apart
  • Annual revaccination with one dose is recommended
  • Available in a 25 x 1 mL dose

ALSO AVAILABLE IN COMBINATION FORMULATION

Professional Leptospirosis

Resources & Studies

Combo Protection

Technical Bulletin

Read about the proven protection NOBIVAC® Canine 1-DAPPv+L4 Vaccine provides to help you protect your patients.  

Download

Quick Guide to Lepto

eBook

A handy guide to protect dogs and prevent the spread of leptospirosis.

Download

Standard Operating Procedure

Video

Learn why it’s important to have a Standard Operating Procedure to reduce the risk of leptospirosis in your practice.

watch

No items to show.

Loading…

Disease & Mortality Study

Revention of Disease and Mortality in Vaccinated Dogs Following Experimental Challenge With Virulent Leptospira. R LaFleur, J Dant, T Wasmoen. Intervet / Schering Plough Animal Health, Elkhorn, NE. Canine Leptospirosis can vary from subclinical infection to illness that ranges from mild to severe, including death, depending on the susceptibility of the dog, virulence of the organism, and route and degree of infection. The objective of this study was to evaluate the ability of a canine Leptospira bacterin to prevent infection and disease following challenge with virulent Leptospira canicola, L. pomona, L. grippotyphosa, or L. icterohaemorrhagiae. Groups of 8-week-old beagles were vaccinated (day 0) and boosted (day 21) with placebo (n = 10) or the 4-way bacterin (n ≥ 20) and subsequently challenged with each serovar. The results demonstrated that blood and various tissue samples from placebo-recipients became reliably infected, and the dogs developed typical clinical signs of Leptospirosis including loss of appetite, ocular congestion, depression, dehydration, jaundice, hematuria, melena, vomiting, petechiae, and death. In addition, placebo-recipients developed kidney and liver dysfunction. In contrast, some vaccine-recipients became infected, but the organisms were cleared quickly from the blood. Vaccinated dogs failed to develop severe clinical disease requiring medical intervention, and no animals died (p > 0.001). A few of the vaccinated dogs developed clinical abnormalities, but the clinical signs remained mild and were self-limiting (p < 0.0001 for each serovar). Administration of the bacterin also prevented thrombocytopenia (p < 0.0001), kidney complications caused by L. canicola (p < 0.0001), L. icterohaemorrhagiae (p < 0.0001), and L. pomona (p = 0.012), and liver dysfunction caused by L. pomona (p < 0.0001) and L. grippotyphosa (p < 0.0001). The results therefore confirmed that vaccinating dogs with the 4-way Leptospira bacterin provided a high degree of protection (99.5%-100%) against the clinical signs of Leptospirosis including mortality.

Urinary Shedding Challenge Study

Prevention of Leptospiremia and Leptospiruria Following Vaccination With a Dappv + 4-way Leptospira Combination Vaccine

Rhonda L. LaFleur, Jennifer C. Dant, Anna L. Tubbs, Huchappa Jayappa, David Sutton, Ian Tarpey

Background: Leptospirosis, characterized by high fever, anorexia, vomiting, abdominal pain, diarrhea, myalgia, polyuria/polydipsia, jaundice, epistaxis, hematuria, and/or reproductive failure, continues to cause considerable morbidity among infected canines. Direct transmission of Leptospira spp. occurs when dogs come into contact with infected urine or ingest infected tissue. After dogs become infected, the spirochetes circulate in the blood for several days,1,3 where they cause extensive damage to the endothelium of small blood vessels (leptospiremia). After the leptospiremic phase, the spirochetes can further colonize various organs, including the kidneys, where dogs can become a carrier and potentially shed organisms in the urine for months (leptospiruria). Leptospira interrogans serovars Canicola and Icterohaemorrhagiae are traditional causative agents of canine leptospirosis, and while the use of bacterins have decreased the prevalence of the disease, significant morbidity can still be attributed to infection with these serovars.

Aim to Work: In this study, we combined inactivated L interrogans serovars Canicola, Pomona, and Icterohaemorrhagiae and L kirschneri serovar Grippotyphosa with Nobivac® Canine 1-DAPPv (Animal Health at Merck & Co., Inc., Kenilworth, NJ USA), a commercially available vaccine that contains modified live canine distemper virus, adenovirus, parainfluenza virus, and parvovirus. We then vaccinated dogs with the combination product and evaluated the ability of the vaccination to prevent leptospiremia and leptospiruria following challenge with viable organisms of each serovar.

 

Read More about this study here

No items to show.

Loading…

TECHNICAL ASSISTANCE

For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318

References:

1. Data on file, Merck Animal Health. 

21. LaFleur RL, Dant JC, Wasmoen TL. Prevention of disease and mortality in vaccinated dogs following experimental challenge with virulent leptospira. J Vet Int Med, May/June 2011, Vol 25, Issue 3; 747. 

22. LaFleur RL, Dant JC, Tubbs AL, et al. Prevention of leptospiremia and leptospiruria following vaccination with a DAPPv + 4-way leptospira combination vaccine. Abstract & Poster, ISCAID meeting, Bristol, UK, 2016. 

23. J.E. Sykes, K. Hartmann, K.F. Lunn, et al. 2010 ACVIM Small Animal Consensus Statement on Leptospirosis: Diagnosis, Epidemiology, Treatment, and Prevention. J Vet Intern Med 2011; 25: 1–13. 

24. Nobivac® Lepto4 [product label], Madison, NJ: Merck Animal Health; 2018. 

25. VANGUARD® L4 [product label]. Florham Park, NJ: Zoetis, Inc; 2018. 

26. RECOMBITEK® 4 Lepto [product label]. Duluth, GA: Boehringer Ingelheim Animal Health; 2018. 

27. ULTRA Duramune® 4L, LEPTOVAX® 4 [product labels]. Greenfield, IN: Elanco; 2018.